Food Science and Technology International | 2021
Clinical application of High-flow nasal cannula oxygen therapy in acute heart failure
Abstract
Dyspnea and hypoxia are the most common symptoms of acute heart failure (AHF) and are the leading cause of emergency care (Gheorghiade & Pang, 2009); respiratory support is the first measure taken during AHF emergency treatment (Mebazaa et al., 2015). HFNC is a new type of respiratory support developed in recent years. HFNC devices allow modification of only two variables – the percentage of oxygen being delivered and the rate of gas flow. There are at this time only two such devices on the market. Both are capable of delivering a mix of air and oxygen with an inspired oxygen fraction (FiO2) ranging between 0.21-1.0. HFNC can partially substitute non-invasive ventilator function, and has higher humidification efficiency and better comfort. It has been proposed that the HFNC can provide several benefits. Among these are maintenance of a constant FiO2, generation of a positive end-expiratory pressure (PEEP), reduction of the anatomical dead space, improvement of mucociliary clearance and reduction in the work of breathing. Therefore, its clinical application is also more and more extensive.